West Pharmaceutical Services, Inc.
WST Healthcare Medical - Instruments & Supplies NYSE
$245.86
+$1.51 (+0.62%)
Open: $241.00 | High: $246.27 | Low: $239.75 | Prev Close: $244.35
Market Cap: $17.71B
Volume: 889K | Avg: 932K
Last updated: March 09, 2026 at 02:05 AMFeatured In
This stock appears in the following dashboards:
Options Activity for WST
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 542
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 36.21 |
| P/B Ratio | 5.60 |
| P/S Ratio | 5.76 |
| EPS | $6.79 |
| Beta | 1.18 |
| Shares Outstanding | 72.02M |
| 52-Week High | $322.34 |
| 52-Week Low | $187.43 |
| SMA 50 | $254.60 |
| SMA 200 | $251.04 |
| Dividend Yield | 0.35% |
| Annual Dividend | $0.86 |
| Next Earnings | April 23, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 35.9% |
| Operating Margin | 20.1% |
| Net Margin | 16.1% |
| ROE | 16.7% |
| ROA | 11.6% |
| Debt/Equity | 0.10 |
| Current Ratio | 3.02 |
| Quick Ratio | 2.34 |
Balance Sheet
| Total Assets | $4.27B |
| Total Liabilities | $1.09B |
| Total Equity | $3.18B |
|
|
|
| Cash | $791.30M |
| Total Debt | $416.70M |
| Net Debt | $-374,600,000 |
Income Statement
| Revenue | $3.07B |
| Gross Profit | $1.10B |
| Operating Income | $617.40M |
| Net Income | $493.70M |
|
|
|
| EBITDA | $723.60M |
| Revenue/Share | $42.51 |
Cash Flow
| Operating CF | $754.80M |
| CapEx | $285.90M |
| Free Cash Flow | $468.90M |
|
|
|
| Book Value/Share | $43.93 |
| Tangible Book/Share | $42.30 |
| Equity/Share | $43.93 |
Technical Indicators
| RSI (14) | 44.95 Neutral |
| MACD |
-0.76
Signal: -1.54
|
| Volatility | 35.92% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +13.18% |
| Sharpe Ratio | 0.44 Fair |
| Volatility (Ann.) | 41.43% High Risk |
| WST (1Y) | +13.18% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +0.15% |
Sector Comparison (Healthcare)
| Metric | WST | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 36.21 | 27.49 | 74% |
| P/B Ratio | 5.6 | -19.63 | 72% |
| ROE (%) | 16.68% | -9.61% | 66% |
| Net Margin (%) | 16.06% | 9.19% | 66% |
| Stock Score | 542 | 543.0 | 45% |
| 1Y Return (%) | +13.18 % | +8.04 % | 62% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WST | $245.86 | $248.67 | $248.74 | $246.95 | $254.45 | $251.00 | 44.95 | -0.76 | 35.92% | 239167 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the WST stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| WST | 3 Dividend Aristocrats to Buy Now Amid the Middle East Crisis | Neutral | zacks.com | Read More |
| WST | Reasons to Add West Pharmaceutical Stock to Your Portfolio Right Now | Neutral | zacks.com | Read More |
| WST | West Pharmaceutical Services, Inc. (WST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| WST | West Pharma CEO Eric Green to retire after 11 years at the helm | Neutral | reuters.com | Read More |
| WST | Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc. | Neutral | prnewswire.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-01 | Finch Norman D. Jr. | officer: SVP, GC & Corporate Secretary | BUY | 3057 | $254.34 | $777517 |
| 2026-03-01 | Green Eric Mark | director, officer: President, CEO and Board Chair | BUY | 16630 | $254.34 | $4229674 |
| 2026-03-01 | Favorite Annette F | officer: Sr. VP & Chief HR Officer | BUY | 1712 | $254.34 | $435430 |
| 2026-03-01 | Campbell Shane Alden | officer: SVP, Proprietary Segment | BUY | 2691 | $254.34 | $684429 |
| 2026-03-01 | McMahon Robert W. | officer: SVP & Chief Financial Officer | BUY | 7337 | $254.34 | $1866093 |
| 2026-03-01 | Poussot Rodolphe Jean | officer: SVP, Strategy & Corporate Dev | BUY | 1040 | $254.34 | $264514 |
| 2026-03-01 | Winters Chad | officer: VP, Chief Accounting Officer | BUY | 808 | $254.34 | $205507 |
| 2026-02-20 | Poussot Rodolphe Jean | officer: SVP, Strategy & Corporate Dev | SELL | 129 | $241.12 | $31236 |
Company Information
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
| CEO | Eric Green |
| Employees | 10600 |
| Country | US |
| IPO Date | 1980-03-17 |
| Exchange | NYSE |
| Website | https://www.westpharma.com |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category